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Abstract
Background: Fibromyalgia is a chronic health condition characterized by widespread
musculoskeletal pain, multiple tender points on physical examination, generalized muscular aching,
stiffness, fatigue, nonrestorative sleep pattern, cognitive dysfunction, and mood disturbance.
Recently, the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Fibromyalgia
Syndrome Workshop ranked and prioritized the domains that should be consistently measured in
fibromyalgia clinical trials, specifically, pain, generic health-related quality of life, fatigue, sleep
quality, and physical function. The focus of these deliberations was exclusively on adult patients, and
to our knowledge, these domains have not been previously tested within a multidimensional
framework in children and adolescents with fibromyalgia.
Methods: An analysis to determine the feasibility, reliability, and validity of the PedsQL™ 4.0
(Pediatric Quality of Life Inventory™) Generic Core Scales, PedsQL™ Multidimensional Fatigue
Scale, and PedsQL™ Rheumatology Module Pain and Hurt Scale as patient-reported outcome
(PRO) measures for pediatric patients with fibromyalgia. The PedsQL™ Scales were completed by
59 families in a pediatric rheumatology clinic in a large children's hospital.
Results: The PedsQL™ evidenced minimal missing responses (0.53% patient self-report, 0.70%
parent proxy-report), achieved excellent reliability for the Generic Core Scales Total Scale Score
(α = 0.88 patient self-report, 0.87 parent proxy-report), the Multidimensional Fatigue Scale Total
Scale Score (α = 0.94 patient self-report, 0.94 parent proxy-report), and acceptable reliability for
the 4-item Rheumatology Module Pain and Hurt Scale (α = 0.68 patient self-report, 0.75 parent
proxy-report). The PedsQL™ Generic Core Scales and Multidimensional Fatigue Scale significantly
distinguished between pediatric patients with fibromyalgia and healthy children. Pediatric patients
with fibromyalgia self-reported severely impaired physical and psychosocial functioning, significantly
lower on most dimensions when compared to pediatric cancer patients receiving cancer treatment,
and significantly lower on all dimensions than pediatric patients with other rheumatologic diseases.
Patients with fibromyalgia self-reported significantly greater pain and fatigue than pediatric patients
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Health and Quality of Life Outcomes 2007, 5:9 http://www.hqlo.com/content/5/1/9with other rheumatologic conditions, and generally more fatigue than pediatric patients receiving
treatment for cancer.
Conclusion: The results demonstrate the excellent measurement properties of the PedsQL™
Scales in fibromyalgia. These PedsQL™ Scales measure constructs consistent with the
recommended OMERACT Fibromyalgia Syndrome Workshop domains. The findings highlight the
severely impaired HRQOL of pediatric patients with fibromyalgia. Regular monitoring of pediatric
patients with fibromyalgia will help identify children and adolescents at risk for severely impaired
HRQOL. These PedsQL™ Scales are appropriate outcome measures for clinical trials and health
services research for pediatric patients with fibromyalgia.
Background
Fibromyalgia (FM) is a chronic health condition charac-
terized by widespread musculoskeletal pain, multiple ten-
der points on physical examination, generalized muscular
aching, stiffness, fatigue, nonrestorative sleep pattern,
cognitive dysfunction, and mood disturbance [1-3]. FM is
considered a clinical syndrome presumably related to cen-
tral neuromodulatory dysregulation [4]. The treatment of
FM is complicated by the fact that there are no objective
findings on the physical examination or laboratory tests
that, in other rheumatologic conditions, confirm the
extent of disease severity and aid in the establishment of a
diagnosis. Consequently, the diagnosis of FM is based on
illness history, exclusion of other causes of symptoms,
verbal self-report, and physical examination [1].
Yunus and Masi were the first to describe the juvenile pri-
mary fibromyalgia syndrome (JPFS) in pediatric patients
[5]. Consistent with the literature regarding adult patients
[6], FM in pediatric patients is more common in girls than
boys [5]. Although there are limited epidemiological data
about the prevalence of FM in children and adolescents, it
accounts for approximately 7–8% of new patient diag-
noses in the pediatric rheumatology clinical practice, with
estimates of population-based schoolchildren prevalence
studies ranging from 1.2% to 7.5% [7].
The lack of physiological markers of disease activity for
FM complicates the clinical decision-making process,
since the treating physician cannot monitor the course of
the illness with objective disease indicators that are avail-
able for other rheumatologic diseases such as juvenile idi-
opathic arthritis. Given the lack of objective outcomes
measures, and the emerging therapies currently being
tested for FM, the need for reliable and valid patient-
reported outcome instruments for FM, including health-
related quality of life instruments, has become urgent [4].
Health-related quality of life assessment in fibromyalgia
Health-related quality of life (HRQOL) has been progres-
sively acknowledged as an essential health outcome meas-
ure in clinical trials and health services research and
evaluation [8-10]. A HRQOL instrument must be multidi-
mensional, consisting at the minimum of the physical,
psychological (including emotional and cognitive), and
social health dimensions delineated by the World Health
Organization [11,12]. Studies with adult patients with FM
have demonstrated that in comparison to healthy con-
trols, patients with FM report substantially lower HRQOL
across multiple domains [13-15].
Health-related quality of life assessment in pediatric 
patients
Although the measurement of HRQOL in pediatric clini-
cal trials has been advocated for a number of years [16],
the emerging paradigm shift toward patient-reported out-
comes (PROs) in clinical trials [12] has provided the
opportunity to further emphasize the value and essential
need for pediatric patient self-report measurement as effi-
cacy outcomes in clinical trials for pediatric chronic health
conditions [17-20]. By definition, patient-reported out-
comes (PROs) are self-report instruments that directly
measure the patient's perceptions of the impact of disease
and treatment as clinical trial endpoints [12]. PROs
include multi-item HRQOL instruments, as well as single-
item symptom measures (e.g., pain intensity visual ana-
logue scale [VAS]) [21-23].
It is well documented in both the adult and pediatric lit-
erature that information provided by proxy-respondents
is not equivalent to that reported by the patient [24,25].
Imperfect agreement between self-report and proxy-
report, termed cross-informant variance [26], has been
consistently documented in the HRQOL measurement of
children with chronic health conditions and healthy chil-
dren [27-34].
While pediatric patient self-report should be considered
the standard for measuring perceived HRQOL [35], there
may be circumstances when the child is too young, too
cognitively impaired, too ill or fatigued to complete a
HRQOL instrument, and parent proxy-report may be
needed in such cases [36]. Further, it is typically parents'
perceptions of their children's HRQOL that influences
healthcare utilization [37-39]. Thus, HRQOL instruments
should be selected that measure the perspectives of bothPage 2 of 12
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pendently related to healthcare utilization, risk factors,
and quality of care [40].
Ideally, parent and child HRQOL instruments should
measure the same constructs with parallel items in order
to make comparisons between self and proxy report more
meaningful [41,42]. Even when children are able to self-
report, parent proxy-report should be considered as a sec-
ondary outcome measure given parents' expanding role in
clinical decision-making and home treatment regimens
for pediatric chronic health conditions [40]. Thus, there is
a clear and defined role for parent proxy-report instru-
ments in the assessment of pediatric HRQOL outcomes.
OMERACT Fibromyalgia Syndrome Workshop domains
Recently, the Outcome Measures in Rheumatoid Arthritis
Clinical Trials (OMERACT) Fibromyalgia Syndrome
Workshop ranked and prioritized the domains that
should be consistently measured in FM clinical trials in
adults, specifically, pain, generic HRQOL, fatigue, sleep
quality, and physical function [4]. To our knowledge,
these domains have not been previously tested within a
multidimensional framework in children and adolescents
with FM.
Consequently, the objectives of the current analyses are to
determine the feasibility, reliability and validity of pediat-
ric patient self-report and parent proxy-report for children
and adolescents with FM utilizing the PedsQL™ 4.0
Generic Core Scales, PedsQL™ Multidimensional Fatigue
Scale, and PedsQL™ Rheumatology Module Pain and Hurt
Scale. These scales were selected for this investigation
since they measure the primary symptom domains identi-
fied by the OMERACT Fibromyalgia Syndrome Workshop
[4].
Based on the extant literature on HRQOL in pediatric
chronic health conditions in general and FM in particular,
we hypothesized that pediatric patients with FM would
self-report significantly lower physical and psychosocial
functioning and greater fatigue than healthy children. We
further examined the agreement between pediatric patient
self-report and parent proxy-report, expecting moderate
agreement based on the extant literature [43] and previ-
ous research with the PedsQL™ in pediatric chronic health
conditions [44-46]. In order to further determine the clin-
ical magnitude of the hypothesized negative impact of FM
on pediatric patient self-reported HRQOL, pain, and
fatigue, we conducted comparative analyses between
pediatric patients with FM and pediatric cancer patients
receiving cancer treatment (chemotherapy and radiation
therapy) and pediatric patients with other rheumatologic
conditions, both groups who have previously demon-
strated impaired self-reported HRQOL, pain, and fatigue
using the PedsQL™ [44-46].
Method
Participants and settings
Pediatric fibromyalgia sample
Participants were 59 children and adolescents ages 8 to 18
years, and their parents (n = 57), diagnosed with FM by
their pediatric rheumatologist using the Yunus & Masi cri-
teria [5]. Pediatric patients with FM were identified
through the appointment schedule at the Pediatric Rheu-
matology Clinic at Rady Children's Hospital and Health
Center, San Diego. Parents of children identified as possi-
ble study participants were informed of the study after
checking in for their appointment, but before being seen
by their healthcare provider. Written parental informed
consent and child assent were obtained.
Patients and parents completed the PedsQL™ 4.0 Generic
Core Scales and PedsQL™ 3.0 Rheumatology Module Pain
and Hurt Scale during a routine rheumatology clinic visit.
The PedsQL™ Multidimensional Fatigue Scale was admin-
istered to patients (n = 29) and parents (n = 26) beginning
approximately midway through participant recruitment
since it was still under development at the initiation of
this field test in FM. The PedsQL™ was self-administered
for both children and their parents. Parents and children
completed the PedsQL™ separately. One parent (79.7%
mothers; 8.5% fathers; 5.1% other, 6.8% missing) com-
pleted the proxy-report version. Trained clinic personnel
were available to answer questions regarding the self-
administered instruments after the instructions had been
given and clarified. This research protocol was approved
by the Institutional Review Board at Children's Hospital
and Health Center, San Diego.
Although the PedsQL™ can be administered for children
ages 2–18, children in this sample were all between the
ages of 8 years and 18 years given that it is relatively
uncommon for young children to have fibromyalgia. The
average age of the 53 girls (89.8%) and 6 boys (10.2%)
was 13.73 years (SD= 2.92). With respect to race/ethnic-
ity, the sample contained 35 (59.3%) White non-His-
panic, 8 (13.6%) Hispanic, 2 (3.4%) Black non-Hispanic,
2 (3.4%) American Indian or Alaskan Native, 1 (1.7%)
other, and 11 (18.6%) missing. Mean socioeconomic sta-
tus (SES) was 46.59 (SD = 12.20), based on the Hollings-
head index, indicating on average a middle-class family
SES [47].
Pediatric cancer sample
The pediatric cancer sample consisted of children and
adolescents ages 8 to 18 years receiving cancer treatment
(chemotherapy and radiation therapy) and their parents
who were randomly matched by age group to the FM sam-Page 3 of 12
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dom sample case selection command [48]. These
participants, derived from the PedsQL™ 3.0 Cancer Mod-
ule field test [44], were recruited from the Hematology/
Oncology Centers at Rady Children's Hospital and Health
Center, San Diego and Childrens Hospital Los Angeles.
Written parental informed consent and child assent were
obtained. The PedsQL™ was self-administered for both
children and their parents. The sample included children
with acute lymphocytic leukemia (n = 38, 46.9%), brain
tumor (n = 8, 9.9%), Hodgkin's lymphoma (n = 6, 7.4%),
non-Hodgkin's lymphoma (n = 5, 6.2%), Wilm's tumor
(n = 1, 1.2%), and other cancers (n = 23, 28.4%). For all
forms combined, the average age of the 39 boys (48.1%)
and 41 girls (50.6%; Missing = 1, 1.2%) was 12.88 years
(SD = 3.28). With respect to race/ethnicity, the sample
contained 39 (48.1%) Hispanic, 30 (37.0%) White non-
Hispanic, 3 (3.7%) Black non-Hispanic, 1 (1.2%) Asian/
Pacific Islander, 1 (1.2%) American Indian or Alaskan
Native, 6 (7.4%) other, and 1 (1.2%) missing. Mean soci-
oeconomic status (SES) was 34.74 (SD = 15.43), based on
the Hollingshead index, indicating on average a lower
middle-class family SES [47].
Pediatric rheumatology sample
The rheumatology sample consisted of children ages 8 to
18 years and their parents who were randomly matched
by age group to the FM sample utilizing the SPSS Version
14.0 statistical software random sample case selection
command [48]. These participants, derived from the Ped-
sQL™ 3.0 Rheumatology Module field test [45] and the
PedsQL™ Multidimensional Fatigue Scale field test in
pediatric rheumatology [46], were recruited from the
Pediatric Rheumatology Clinic at Rady Children's Hospi-
tal and Health Center, San Diego. Written parental
informed consent and child assent were obtained. The
PedsQL™ was self-administered for both children and
their parents. For all forms combined, the average age of
the 42 boys (26.8%) and 114 girls (72.6%; Missing = 1,
0.6%) was 13.43 years (SD = 3.32). With respect to race/
ethnicity, the sample contained 64 (40.8%) White non-
Hispanic, 30 (19.1%) Hispanic, 8 (5.1%) Asian/Pacific
Islander, 6 (3.8%) Black non-Hispanic, 2 (1.3%) Ameri-
can Indian or Alaskan Native, 3 (1.9%) other, and 44
(28.0%) missing. Mean socioeconomic status (SES) was
46.79 (SD = 14.63), based on the Hollingshead index,
indicating on average a middle-class family SES [47].
Healthy children sample: Generic Core Scales
Participants included children and adolescents ages 8 to
18 years and their parents who were randomly matched
by age group and gender to the FM sample utilizing the
SPSS Version 14.0 statistical software random sample case
selection command [48]. "Healthy" children and adoles-
cents, defined as children and adolescents without parent-
identified chronic illness or disability, were derived from
the PedsQL™ 4.0 Generic Core Scales DatabaseSM and were
recruited from either a California State Children's Health
Insurance Program (SCHIP) (n= 1758; 51.4%) [49] or
from a school-based study within the San Diego Unified
School District (n = 1662; 48.6%) [50]. Children and par-
ents completed the PedsQL™ 4.0 Generic Core Scales,
which was self-administered for both children and their
parents. For all forms combined, the average age of the
342 boys (10.0%) and 3078 girls (90.0%) was 11.54 years
(SD = 2.44). The sample was heterogeneous with respect
to race/ethnicity with 1521 (44.5%) Hispanic, 790
(23.1%) Asian/Pacific Islander, 553 (16.2%) White non-
Hispanic, 288 (8.4%) Black non-Hispanic, 11 (0.3%)
American Indian or Alaskan Native, 54 (1.6%) other, and
203 (5.9%) missing. The statewide SCHIP sample and
large metropolitan school district sample were represent-
ative of low to low-middle income families.
Healthy children sample: Multidimensional Fatigue Scale
Participants were healthy children ages 5 to 18 years and
parents of healthy children ages 2 to 18 years derived from
the PedsQL™ Multidimensional Fatigue Scale field test in
pediatric rheumatology [46]. Participants were not ran-
domly matched by age and gender to the FM sample given
the small healthy children sample available. This healthy
sample was recruited at the Orthopedic Clinic in Rady
Children's Hospital and Health Center, San Diego, and
included patients who presented with broken bones or
fractures 6 months prior to assessment with the PedsQL™.
All patients were identified by the clinic nurse as being
healthy at the time of assessment (e.g., no current prob-
lems due to their orthopedic injury). Participants were
administered the PedsQL™ Multidimensional Fatigue
Scale Acute Version (7 day recall period) via telephone,
after obtaining informed consent and assent. For all forms
combined, the average age of the 69 boys (67.6%) and 30
girls (29.4%; Missing = 3, 2.9%) was 9.89 years (SD =
5.02). The sample was heterogeneous with respect to race/
ethnicity with 47 (46.1%) Hispanic, 28 (27.5%) White
non-Hispanic, 6 (5.9%) Black non-Hispanic, 2 (2.0%)
Asian/Pacific Islander, 1 (1.0%) American Indian or
Alaskan Native, 14 (13.7%) other, and 4 (3.9%) missing.
Mean socioeconomic status (SES) was 36.46 (SD =
16.05), based on the Hollingshead index, indicating on
average a lower middle-class family SES [47].
Measures
The PedsQL™ 4.0 (Pediatric Quality of Life Inventory™ Version 4.0)
The 23-item PedsQL™ 4.0 Generic Core Scales encompass:
1) Physical Functioning (8 items), 2) Emotional Func-
tioning (5 items), 3) Social Functioning (5 items), and 4)
School Functioning (5 items), and were developed
through focus groups, cognitive interviews, pre-testing,
and field testing measurement development protocolsPage 4 of 12
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complete [51].
The PedsQL™ 4.0 Generic Core Scales are comprised of
parallel child self-report and parent proxy-report formats.
Child self-report includes ages 5–7, 8–12, and 13–18
years. Parent proxy-report includes ages 2–4 (toddler), 5–
7 (young child), 8–12 (child), and 13–18 (adolescent),
and assesses parent's perceptions of their child's HRQOL.
The items for each of the forms are essentially identical,
differing in developmentally appropriate language, or first
or third person tense. The instructions ask how much of a
problem each item has been during the past one month.
A 5-point response scale is utilized across child self-report
for ages 8–18 and parent proxy-report (0 = never a prob-
lem; 1 = almost never a problem; 2 = sometimes a prob-
lem; 3 = often a problem; 4 = almost always a problem).
Items are reverse-scored and linearly transformed to a 0–
100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that
higher scores indicate better HRQOL. Scale Scores are
computed as the sum of the items divided by the number
of items answered (this accounts for missing data). If
more than 50% of the items in the scale are missing, the
Scale Score is not computed. This accounts for the differ-
ences in sample sizes for scales reported in the Tables.
Although there are other strategies for imputing missing
values, this computation is consistent with the previous
PedsQL™ peer-reviewed publications, as well as other
well-established HRQOL measures [51-53]. The Physical
Health Summary Score (8 items) is the same as the Phys-
ical Functioning Scale. To create the Psychosocial Health
Summary Score (15 items), the mean is computed as the
sum of the items divided by the number of items
answered in the Emotional, Social, and School Function-
ing Scales.
PedsQL™ Multidimensional Fatigue Scale
The 18-item PedsQL™ Multidimensional Fatigue Scale
encompasses: 1) General Fatigue (6 items, e.g., "I feel
tired."; "I feel too tired to do things that I like to do."), 2)
Sleep/Rest Fatigue (6 items, e.g., "I feel tired when I wake
up in the morning."; "I rest a lot."), and 3) Cognitive
Fatigue (6 items, e.g., "It is hard for me to keep my atten-
tion on things."; "It is hard for me to remember what peo-
ple tell me."), with demonstrated reliability and validity
in pediatric rheumatology [46]. The format, instructions,
Likert scale, and scoring method are identical to the Ped-
sQL™ 4.0 Generic Core Scales, with higher scores indicat-
ing better HRQOL (fewer problems or symptoms).
PedsQL™ Rheumatology Module Pain and Hurt Scale
The 22-item multidimensional PedsQL™ 3.0 Rheumatol-
ogy Module includes a 4-item Pain and Hurt Scale (e.g., "I
ache or hurt in my joints and/or muscles," "I feel stiff in
the morning or when I sit too long"), with demonstrated
reliability and validity in pediatric rheumatology [45].
The format, instructions, Likert scale, and scoring method
are identical to the PedsQL™ 4.0 Generic Core Scales, with
higher scores indicating better HRQOL (fewer problems
or symptoms).
PedsQL™ Family Information Form
The PedsQL™ Family Information Form [51] was com-
pleted by parents. The PedsQL™ Family Information Form
contains demographic information including the child's
date of birth, gender, race/ethnicity, and parental educa-
tion and occupation information required to calculate the
Hollingshead four factor socioeconomic status (SES)
index [47].
Statistical analyses
The feasibility of the PedsQL™ Scales as outcome meas-
ures for pediatric patients with FM was determined from
the percentage of missing values for each item [52]. Scale
internal consistency reliability was determined by calcu-
lating Cronbach's coefficient alpha [54]. Scales with relia-
bilities of 0.70 or greater are recommended for comparing
patient groups, while a reliability criterion of 0.90 is rec-
ommended for analyzing individual patient scale scores
[55,56].
Construct validity was determined utilizing the known-
groups method. The known-groups method compares
scale scores across groups known to differ in the health
construct being investigated [52,57]. In this study, analy-
sis of variance with Tukey post-hoc tests was used to com-
pare groups differing in known health status (pediatric
patients with FM and healthy children) on the PedsQL™
4.0 Generic Core Scales and the PedsQL™ Multidimen-
sional Fatigue Scale. We also explored comparisons
between the Generic Core Scales and Multidimensional
Fatigue Scale for pediatric patients with FM with pediatric
patients with cancer on-treatment and pediatric patients
with other rheumatologic conditions. We further com-
pared pain reports between pediatric patients with FM
with pediatric patients with other rheumatologic condi-
tions using independent sample t-tests. In order to deter-
mine the magnitude of the differences between pediatric
patients with FM and healthy children, effect sizes were
calculated [58]. Effect size as utilized in these analyses was
calculated by taking the difference between the healthy
sample mean and the FM sample mean, divided by the
healthy sample standard deviation. Effect sizes for differ-
ences in means are designated as small (.20), medium
(.50), and large (.80) in magnitude [58].
Construct validity for the PedsQL™ Scales in FM was fur-
ther examined through an analysis of Pearson's Product
Moment Correlations among the Generic Core Scales andPage 5 of 12
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the conceptualization of disease-specific symptoms as
causal indicators of generic HRQOL, and the extant litera-
ture on adult patients with FM, it was anticipated that
more severe pain and fatigue would be associated with
more impaired generic HRQOL. Computing the intercor-
relations among scales provides additional information
on the construct validity of an instrument [56]. Pearson's
Product Moment Correlation coefficient effect sizes are
designated as small (.10–.29), medium (.30–.49), and
large (≥ .50) [58]. Intercorrelations were expected to dem-
onstrate medium to large effect sizes.
Agreement between child self-report and parent proxy-
report was determined through two-way mixed effect
model (absolute agreement, single measure) Intraclass
Correlations (ICC) [59]. The ICC offers an index of abso-
lute agreement given that it takes into account the ratio
between subject variability and total variability [59,60].
Intraclass Correlations are designated as ≤ 0.40 poor to
fair agreement, 0.41–0.60 moderate agreement, 0.61–
0.80 good agreement, and 0.81–1.00 excellent agreement
[61,62]. Statistical analyses were conducted using SPSS
Version 14.0 for Windows [48].
Results
Feasibility
To assess instrument feasibility, the percentage of missing
values was calculated. The overall percentage of missing
item responses across the PedsQL™ scales for patient self-
report and parent proxy-report for the FM sample was
0.53% and 0.70%, respectively. For patient self-report and
parent proxy-report, the percentage of missing item
responses for the FM sample on the PedsQL™ 4.0 Generic
Core Scales was 0.40% and 0.96%, respectively. For
patient self-report and parent proxy-report, the percentage
of missing item responses for the FM sample on the Ped-
sQL™ Multidimensional Fatigue Scale was 0.98% and
0.27%, respectively. For patient self-report and parent
proxy-report, the percentage of missing item responses for
the FM sample on the PedsQL™ Rheumatology Module
Pain and Hurt scale was 0.44% and 0.00%, respectively.
Internal consistency reliability
Internal consistency reliability alpha coefficients for the
PedsQL™ 4.0 Generic Scales and summary scores are pre-
sented in Table 1. Internal consistency reliability alpha
coefficients for the PedsQL™ Multidimensional Fatigue
scales and the PedsQL™ Rheumatology Module Pain and
Hurt scale are presented in Table 2. On the PedsQL™ 4.0
Generic Core Scales and Multidimensional Fatigue Scale,
all the patient self-report scales and parent proxy-report
scales met or exceeded the minimum reliability standard
of 0.70 required for group comparisons, while the Generic
Core Total Scale Score and Total Fatigue Scale Score for
both child self-report and parent proxy-report approached
or exceeded the reliability criterion of 0.90 recommended
for analyzing individual patient scale scores. On the Ped-
sQL™ Rheumatology Module Pain and Hurt Scale, the
child self-report and parent proxy-report alpha coeffi-
cients approached or exceeded the minimum reliability
standard of 0.70 required for group comparisons.
Table 1: PedsQL™ 4.0 Generic Core Scales Scores for Child Self-Report and Parent Proxy-Report across Samples and Reliability for 
Fibromyalgia Sample
Fibromyalgiaa Cancerb Rheumatologyc Healthyd Differences Effect 
Size
Scale α Mean SD Mean SD Mean SD Mean SD
Self-Report (N = 56) (N = 57) (N = 74) (N = 154) (N = 2873)
Total Score 0.88 55.85 15.16 68.48 15.25 76.01 15.88 82.70 13.20 a<b,c,d*** 2.03
Physical Functioning 0.85 45.40 19.86 63.03 23.90 71.72 22.24 86.29 13.69 a<b,c,d*** 2.99
Psychosocial Health 0.84 61.45 16.25 71.78 13.79 78.33 14.57 80.80 14.55 a<b,c,d*** 1.33
Emotional Functioning 0.78 53.77 22.41 67.91 18.60 75.75 19.21 76.60 18.72 a<b,c,d*** 1.22
Social Functioning 0.70 74.47 18.29 79.70 17.73 84.67 16.27 85.27 17.15 a<c**; a<d*** 0.63
School Functioning 0.74 55.74 20.46 67.61 19.37 75.07 17.44 80.51 16.13 a<b,c,d*** 1.54
Proxy-Report (N = 56) (N = 57) (N = 78) (N = 131) (N = 3371)
Total Score 0.87 52.04 15.17 58.23 19.24 73.41 17.47 78.78 16.58 a<c,d*** 1.61
Physical Functioning 0.76 43.37 19.01 53.22 27.11 69.07 23.66 80.53 21.11 a<b*; a<c,d*** 1.76
Psychosocial Health 0.85 56.70 16.41 61.25 17.84 75.73 16.73 77.82 16.39 a<c,d*** 1.29
Emotional Functioning 0.76 48.95 19.47 57.12 22.34 72.56 20.38 77.71 17.76 a<b*; a<c,d*** 1.62
Social Functioning 0.71 67.02 19.70 70.24 19.42 79.84 19.72 80.42 20.88 a<c**; a<d*** 0.64
School Functioning 0.75 53.77 20.55 57.35 22.20 75.15 19.90 75.32 20.14 a<c,d*** 1.07
*p < .05, **p < .01, ***p < .001 based on Tukey post-hoc analysis. Effect sizes are designated as small (.20), medium (.50), and large (.80). Effect sizes 
represent the magnitude in the differences between the Fibromyalgia and Healthy Children samples only. α = Cronbach internal consistency 
reliability coefficient alpha.Page 6 of 12
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Tables 1 and 2 present the means and standard deviations
of the PedsQL™ 4.0 Generic Core Scales and Multidimen-
sional Fatigue Scale scores for patient self-report and par-
ent proxy-report for pediatric patients with FM and
healthy children. For all PedsQL™ 4.0 Generic Core Scales
and summary scores, pediatric patients with FM and their
parents reported statistically significant lower HRQOL
than healthy children. Pediatric patients with FM and
their parents also reported significantly worse fatigue than
healthy children. Most effect sizes were in the large range.
Comparison to pediatric cancer and pediatric 
rheumatology
Tables 1 and 2 also present the means and standard devi-
ations of the PedsQL™ 4.0 Generic Core Scales and Multi-
dimensional Fatigue Scale scores for patient self-report
and parent proxy-report for pediatric patients with cancer
on-treatment and pediatric patients with rheumatologic
conditions other than FM. Table 1 demonstrates that
across the PedsQL™ 4.0 Generic Core Scales and summary
scores, with the exception of the Social Functioning Scale,
children with FM in this sample reported statistically sig-
nificant lower HRQOL than children with cancer on-treat-
ment and children with a variety of rheumatologic
conditions. In addition, pediatric patients with FM
reported significantly worse total fatigue and general
fatigue than children with cancer on-treatment and signif-
icantly worse fatigue across all the fatigue dimensions
than pediatric patients with other rheumatologic condi-
tions. Table 2 also presents the means and standard devi-
ations of the PedsQL™ 3.0 Rheumatology Module Pain
and Hurt Scale between pediatric patients with FM and
pediatric patients with other rheumatologic conditions.
Pediatric patients with FM and their parents reported sig-
nificantly worse pain than pediatric patients with other
rheumatologic conditions and their parents.
Intercorrelations among PedsQL™ Scales
Table 3 shows the intercorrelations among the Generic
Core Scales and summary scores with the pain and fatigue
scales. More severe pain and fatigue was significantly cor-
related with more impaired generic HRQOL. These inter-
correlations are in the large effect size range.
Parent/child agreement
Table 3 presents two-way mixed effect model (absolute
agreement, single measure) Intraclass Correlations (ICC)
between pediatric patients with FM self-report and parent
proxy-report across the PedsQL™ scales. Most ICCs are in
the range of moderate to good agreement, with the great-
est overall agreement on the fatigue and pain scales. On
the PedsQL™ 4.0 Generic Core Scales, the greatest agree-
ment is on the Psychosocial Health Summary Score and
Emotional Functioning Scale.
Discussion
These analyses demonstrate the feasibility, reliability and
validity of the PedsQL™ as a multidimensional pediatric
patient-reported outcome instrument for fibromyalgia
consistent with the OMERACT Fibromyalgia Syndrome
Workshop recommendations [4]. These PedsQL™ Scales
Table 2: PedsQL™ Multidimensional Fatigue Scale and Rheumatology Module Pain and Hurt Scale for Child Self-Report and Parent 
Proxy-Report across Samples and Reliability for Fibromyalgia Sample
Fibromyalgiaa Cancerb Rheumatologyc Healthyd Differences Effect 
Size
Scale α Mean SD Mean SD Mean SD Mean SD
Self-Report (N = 28) (N = 29) (N = 75) (N = 152) (N = 52)
Total Fatigue 0.94 55.48 21.19 70.23 15.68 76.68 20.52 80.49 13.33 a<b**; a<c,d*** 1.88
General Fatigue 0.91 48.97 25.14 71.69 19.42 76.82 23.19 85.34 14.95 a<b,c,d*** 2.43
Sleep/Rest Fatigue 0.76 52.36 21.08 64.50 21.73 71.77 24.27 75.00 18.76 a<c,d*** 1.21
Cognitive Fatigue 0.91 65.17 24.30 74.49 19.10 81.30 20.83 81.14 17.43 a<c,d** 0.92
Pain and Hurt Scale 0.68 32.93 26.88 NA 67.11 27.54 NA a<c*** NA
Proxy-Report (N = 26) (N = 26) (N = 79) (N = 125) (N = 102)
Total Fatigue 0.94 54.19 18.99 64.05 19.08 75.78 20.81 89.63 11.38 a<c,d*** 3.11
General Fatigue 0.89 49.68 21.92 60.04 23.39 73.11 24.65 89.30 13.33 a<c,d*** 2.97
Sleep/Rest Fatigue 0.84 48.85 21.30 56.97 24.37 72.86 23.85 88.86 14.72 a<c,d*** 2.72
Cognitive Fatigue 0.96 64.10 22.70 75.14 21.37 81.83 19.39 90.72 15.15 a<c,d*** 1.76
Pain and Hurt Scale 0.75 32.35 25.93 NA 65.33 28.96 NA a<c*** NA
*p < .05, **p < .01, ***p < .001 based on Tukey post-hoc analysis. Effect sizes are designated as small (.20), medium (.50), and large (.80). Effect sizes 
represent the magnitude in the differences between the Fibromyalgia and Healthy Children samples only. α = Cronbach internal consistency 
reliability coefficient alpha. Healthy sample completed the Acute Version (7-day recall) of the PedsQL™ Multidimensional Fatigue Scale. Sample size 
for the Rheumatology Module Pain and Hurt Scale for Child Self-Report for Fibromyalgia sample equals 57 and for Rheumatology sample equals 
150. Sample size for the Rheumatology Module Pain and Hurt Scale for Parent Proxy-Report for Fibromyalgia sample equals 57 and for 
Rheumatology sample equals 126. NA = not applicable.Page 7 of 12
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be consistently measured in FM clinical trials, specifically,
pain, generic HRQOL, fatigue, sleep quality, and physical
function [4]. In addition, in adult patients with FM, recent
evidence suggests the importance of measuring cognitive
difficulties ("fibrofog"), frequently reported by adult
patients with FM as memory and attention problems [3].
The PedsQL™ Cognitive Fatigue Scale measures the con-
struct of cognitive problems as delineated in the adult FM
literature, and to our knowledge, represents the first meas-
urement presentation of this construct in pediatric
patients with FM.
Items on the PedsQL™ Scales had minimal missing
responses, suggesting that pediatric patients with FM and
their parents are willing and able to provide good quality
data regarding the patient's HRQOL. The PedsQL™ self-
report and proxy-report internal consistency reliabilities
generally exceeded the recommended minimum alpha
coefficient standard of 0.70 for group comparisons. The
PedsQL™ Generic Core Scales Total Score and Multidi-
mensional Fatigue Scale Total Score for pediatric patient
self-report and parent proxy-report approached or
exceeded an alpha of 0.90, recommended for individual
patient analysis [55], making the Generic Core Scales
Total Scale Score suitable as a summary score for the pri-
mary analysis of HRQOL outcome in clinical trial analyses
for pediatric patients with FM, with the PedsQL™ Psycho-
social Health Summary Score, the Multidimensional
Fatigue Scale Total Score, and individual scales suitable
alternatively as either the primary or secondary outcome
score depending on the intent of a particular clinical trial.
As hypothesized, pediatric patients with FM self-reported
significantly lower PedsQL™ scores on dimensions of
physical and psychosocial health and fatigue in compari-
son to healthy children. These findings are consistent with
findings in adult patients with FM using the SF-36 [13-
15]. We believe the consistency of the present findings in
which differences between healthy children and pediatric
patients with FM for both child self-report and parent
proxy-report support the magnitude of the reported
impairment in these pediatric patients with FM. This illus-
trates the benefits of the PedsQL™ Measurement Model in
which both child self-report and parent proxy-report are
measured [28].
The comparisons between pediatric patients with FM with
pediatric cancer patients receiving cancer treatment and
those pediatric patients with other rheumatologic diseases
are useful in understanding the relative clinical impact of
fibromyalgia on HRQOL. The extant literature on the
adaptation of children with chronic physical health con-
ditions demonstrates that children with chronic physical
health conditions are reported to not only experience
lower physical functioning, but also manifest lower emo-
tional, social, and school functioning in comparison to
healthy children [63]. The findings that pediatric patients
with FM report physical and psychosocial health generally
lower than children receiving chemotherapy and radia-
tion for the treatment of pediatric cancer provide further
insight into the comparative negative impact of this
chronic health condition on HRQOL in comparison to
other serious pediatric chronic conditions. The findings
that pediatric patients with FM, whose examinations and
laboratory tests are generally normal, demonstrated sig-
nificantly lower overall HRQOL and more severe pain and
fatigue than pediatric patients with other rheumatologic
conditions, whose examinations and tests are generally
Table 3: Intercorrelations among PedsQL™ Scales for Child Self-Report and Parent Proxy-Report for Fibromyalgia Sample
Scale TG PF PH EF SF SchF TF GF S/RF CF P/HS
Total Generic Core (TG) 0.63*** 0.79*** 0.92*** 0.71*** 0.68*** 0.81*** 0.81*** 0.81*** 0.67** 0.69*** 0.72***
Physical Functioning (PF) 0.80*** 0.47*** 0.48*** 0.27* 0.40** 0.49*** 0.75*** 0.74*** 0.61** 0.64** 0.63***
Psychosocial Health (PH) 0.93*** 0.51*** 0.66*** 0.83*** 0.71*** 0.84*** 0.69*** 0.69*** 0.57** 0.58** 0.62***
Emotional Functioning (EF) 0.73*** 0.44** 0.76*** 0.66*** 0.35** 0.58*** 0.50* 0.49* 0.31 0.49* 0.51***
Social Functioning (SF) 0.80*** 0.45*** 0.85*** 0.45** 0.49*** 0.40** 0.45* 0.47* 0.58** 0.21 0.43**
School Functioning (SchF) 0.77*** 0.38** 0.85*** 0.44** 0.65*** 0.59*** 0.71*** 0.68*** 0.47* 0.73*** 0.54***
Total Fatigue (TF) 0.75*** 0.61** 0.62** 0.53* 0.40 0.63** 0.81*** 0.93*** 0.84*** 0.90*** 0.64**
General Fatigue (GF) 0.77*** 0.70*** 0.60** 0.55** 0.38 0.52* 0.89*** 0.78*** 0.72*** 0.76*** 0.67***
Sleep/Rest Fatigue (S/RF) 0.53* 0.39 0.46* 0.41 0.33 0.38 0.84*** 0.74*** 0.77*** 0.62** 0.48*
Cognitive Fatigue (CF) 0.59** 0.44* 0.50* 0.38 0.30 0.71*** 0.80*** 0.54* 0.45* 0.75*** 0.53**
Pain and Hurt Scale (P/HS) 0.64*** 0.53*** 0.58*** 0.56*** 0.42** 0.44** 0.63** 0.66** 0.63** 0.34 0.73***
Pearson's product moment correlations for patient self-report above diagonal, Pearson's product moment correlations for parent proxy-report 
below diagonal, and two-way mixed effect model (absolute agreement, single measure) Intraclass Correlations (ICCs) for patient/parent agreement 
on diagonal. Effect sizes are designated as small (0.10), medium (0.30), and large (0.50) for Pearson's product moment correlations. ICCs are 
designated as ≤ 0.40 poor to fair agreement, 0.41–0.60 moderate agreement, 0.61–0.80 good agreement, and 0.81–1.00 excellent agreement. *p < 
.05, **p <. 01, ***p < .001.Page 8 of 12
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ing HRQOL outcomes in these children and adolescents.
These findings with the PedsQL™ Scales have potential
clinical implications for the healthcare needs of children
with FM. Given the degree of reported impairment in their
HRQOL, the urgent need for efficacious treatments is
quite evident. The immediate and long-term conse-
quences of untreated or under-treated FM appears quite
severe for these children, their families, and society as a
whole [7,64]. The challenge for health care is to identify
and enroll pediatric patients with FM in high quality evi-
dence-based comprehensive healthcare services in order
to mitigate the potential long-term negative consequences
on patient HRQOL. For chronic health conditions such as
fibromyalgia, HRQOL and symptom scales completed by
patients may be the only indicators of disease activity and
treatment effect [21-23]. In such patient populations,
PROs are often indicated as the primary end-points for
drug approval [21-23]. Given that pharmaceutical and
nonpharmaceutical treatment regimens for adults with
FM are emerging [65-68], trials which evaluate the impact
of similar regimens on the patient-reported health out-
comes of pediatric patients with FM are urgently needed
[7,64,69].
Finally, while self-report is considered the standard for
measuring perceived HRQOL, it is typically parents' per-
ceptions of their children's HRQOL that influences
healthcare utilization [37-39]. Thus, the imperfect agree-
ment observed between child self-report and parent
proxy-report supports the need to measure the perspec-
tives of both the child and parent in evaluating pediatric
HRQOL since these perspectives may be independently
related to healthcare utilization and risk factors. The avail-
ability of a validated parent proxy-report measure in FM
provides the opportunity to estimate child HRQOL when
the child is either unable or unwilling to complete the
HRQOL measure. Although the intercorrelations between
child and parent report across the physical, psychosocial,
fatigue and pain domains might be expected to follow the
conceptualization that more observable domains (i.e.,
physical functioning) would yield higher intercorrela-
tions, this has not necessarily been the case in either Ped-
sQL™ publications across various pediatric chronic health
conditions, or in the published literature with other
HRQOL instruments. In a comprehensive review, Eiser
[70] found mixed results in terms of higher intercorrela-
tions between self and proxy report of physical function-
ing across pediatric HRQOL instruments, with most
studies demonstrating this effect, while some others did
not. In a condition such as FM that is highly associated
with significant pain, fatigue, and emotional distress, par-
ents may be more acutely attuned to these symptoms, and
consequently their perception of their child's HRQOL on
these domains may more closely align with their child's
perceptions.
The present findings have several potential limitations.
Given that the comparative analyses were with an exiting
database, we were only able to match the FM sample to
the pediatric cancer and rheumatology samples by age,
not gender, given the small sample sizes for these chronic
health conditions. Other sociodemographic differences of
these existing databases may have further influenced the
comparative findings with healthy children, and pediatric
patients with cancer and other rheumatologic conditions;
however, our findings are consistent with the literature on
adult patients with FM. Further, the PedsQL™ Multidi-
mensional Fatigue Scale was not administered initially in
our FM recruitment efforts, and thus we report a smaller
sample size for analyses here. Additionally, sensitivity and
responsiveness data were not available for these analyses;
however, previous PedsQL™ research with patients with
rheumatologic and other chronic health conditions have
demonstrated the sensitivity and responsiveness of the
PedsQL™ Scales [17,20,45,71-73]. Finally, we have no
information on nonparticipants given the requirements
of the local IRB.
Conclusion
These PedsQL™ findings demonstrate the feasibility and
measurement properties required for pediatric clinical tri-
als and health services research in pediatric patients with
fibromyalgia. As a chronic musculoskeletal pain syn-
drome with no identifiable cause and no physiological
markers of disease activity, FM represents a significant
challenge in the clinical decision-making process. The
treating physician cannot monitor the course of the illness
with objective disease indicators that are available for
other rheumatologic diseases, and thus is dependent on
patient self-report. These PedsQL™ Scales provide a meas-
urement approach that has great potential as outcome
measures in the clinical setting in this regard. Further,
pediatric patient-reported outcomes should be considered
as the standard for HRQOL measurement in pediatric
clinical trials in which patient health-related quality of life
is investigated in FM. In this way, the voices of the chil-
dren will be heard in matters pertaining to their health
and well-being given the perspective that "some treatment
effects are known only to the patient" [12]. Measuring per-
ceived health from the perspective of pediatric patients
with fibromyalgia provides a level of accountability con-
sistent with the Institute of Medicine report on the quality
of care [74]. As the consumers of pediatric healthcare,
children and their parents are uniquely positioned to give
their perspectives on healthcare quality through their per-
ceptions of patient health-related quality of life.Page 9 of 12
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